AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOPHARMA, INC. on June 9, 2025. The filing primarily addresses the closing of a public offering of common stock and provides updates regarding the company's product, EXXUA (gepirone) extended-release tablets.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The only quantitative financial data disclosed is the post-offering share count.
- Shares Outstanding: 8,976,914 shares of Common Stock issued and outstanding as of June 9, 2025, following the closing of the public offering.
Material Changes
The primary material change reported is the completion of a public offering of common stock, which increased the total number of shares outstanding to 8,976,914. Additionally, the company announced details regarding the commercialization plan for EXXUA.
Guidance, Outlook, and Management Commentary
Management has scheduled a conference call and live audio webcast for Wednesday, June 11, 2025, at 4:30 p.m. Eastern time. The call will discuss the EXXUA opportunity, the related commercialization plan, and answer questions. A replay will be available on the company's website and via telephone at the company's discretion.
Investor Verification Checklist
- Verify the final terms and net proceeds of the public offering of common stock closed on June 9, 2025.
- Review the attached press release (Exhibit 99.1) for specific details on the EXXUA commercialization strategy.
- Confirm the date and access details for the conference call scheduled for June 11, 2025.
- Monitor future filings for updated financial statements reflecting the capital raised from the offering.